The effect of pioglitazone on weight, lipid profile and liver enzymes in type 2 diabetic patients

Therapeutic Advances in Endocrinology and Metabolism

Volumn 6, Issue 2, 2015, Pages 56-60

  Aghamohammadzadeh, Nasser ^a   Niafar, Mitra ^a   Dalir Abdolahinia, Elham ^a   Najafipour, Farzad ^a   Gharebaghi, Saeed Mohamadzadeh ^a   Adabi, Khadijeh ^b   Abdolahinia, Elaheh Dalir ^c   Ahadi, Hamidreza ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ZANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

lipid profile; liver enzyme; pioglitazone; type 2 diabetes mellitus

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; LIVER ENZYME; LOW DENSITY LIPOPROTEIN; PIOGLITAZONE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL TRIAL; DIABETES CONTROL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

EID: 84930577859     PISSN: 20420188     EISSN: 20420196     Source Type: Journal    
DOI: 10.1177/2042018815574229     Document Type: Article

References (32)

1. Aghamohammadzadeh N. Tabrizi A. Niafar M. (2010) Efficacy of adding glutazone to the maximum dose of glibenclamide and metformin resistant on type 2 diabetic patients. Casp J Intern Med 1: 9–11.
2. Al-Azzam S. Alomari M. Khader Y. Almahasneh F. Muflih S. Altawalbeh S. (2012) Effects of pioglitazone add-on to gliclazide and metformin on glycemic control in patients with type 2 diabetes. Endocr Res 37: 7–11.
3. Bajaj M. Suraamornkul S. Piper P. Hardies L. Glass L. Cersosimo E. et al. (2004) Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab 89: 200–206.
4. Belfort R. Harrison S. Brown K. Darland C. Finch J. Hardies J. et al. (2006) A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355: 2297–2307.
5. Browning J. Horton J. (2004) Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 114: 147–152.
6. Ceriello A. Johns D. Widel M. Eckland D. Gilmore K. Tan M. (2005) Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes. Diabetes Care 28: 266–272.
7. Chawla S. Kaushik N. Singh N. Ghosh R. Saxena A. (2013) Effect of addition of either sitagliptin or pioglitazone in patients with uncontrolled type 2 diabetes mellitus on metformin: A randomized controlled trial. J Pharmacol Pharmacother 4: 27–32.
8. Chong S. Subramaniam M. Chan Y. Chua H. Liow P. Pek E. et al. (2009) Depressive symptoms and diabetes mellitus in an Asian multiracial population. Asian J Psychiatr 2: 66–70.
9. Defronzo R. Mehta R. Schnure J. (2013) Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus. Hosp Pract 41: 132–147.
10. Derosa G. (2010) Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: Comparison with other oral antihyperglycaemic agents. Drugs 70: 1945–1961.
11. Ditschuneit H. (2006) Do meal replacement drinks have a role in diabetes management? Nestle Nutr Workshop Ser Clin Perform Programme 11: 171–179.
12. Erlich D. Slawson D. Shaughnessy A. (2013) Diabetes update: new drugs to manage type 2 diabetes. FP Essent 408: 20–24.
13. Fonseca V. (2003) Effect of thiazolidinediones on body weight in patients with diabetes mellitus. A J Med 115: 42S–48S.
14. Golden S. Brown A. Cauley J. Chin M. Gary-Webb T. Kim C. et al. (2012) Health disparities in endocrine disorders: biological, clinical, and nonclinical factors - an Endocrine Society scientific statement. J Clin Endocrinol Metab 97: E1579-E1639.
15. Gross B. Staels B. (2007) PPAR agonists: multimodal drugs for the treatment of type-2 diabetes. Best Pract Res Clin Endocrinol Metab 21: 687–710.
16. Grove J. Daly A. Bassendine M. Day C. (1997) Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis. Hepatology 26: 143–146.
17. Krauss R. (2004) Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 27: 1496–1504.
18. Lee Y. Song S. Kim K. Cho Y. Choi Y. Yun Y. et al. (2013) Glycemic effectiveness of metformin-based dual-combination therapies with sulphonylurea, pioglitazone, or DPP4-inhibitor in drug-naïve Korean type 2 diabetic patients. Diabetes Metab J 37: 465–474.
19. Miyazaki Y. Mahankali A. Matsuda M. Mahankali S. Hardies J. Cusi K. et al. (2002) Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 87: 2784–2791.
20. Nafrialdi. (2012) Efficacy and safety of pioglitazone in type 2 diabetes mellitus: a postmarketing observational study. Acta Med Indones 44: 28–34.
21. Neuschwander-Tetri B. Caldwell S. (2003) Nonalcoholic steatohepatitis: summary of AASLD single topic conference. Hepatology 37: 1202–1219.
22. Pavo I. Jermendy G. Varkonyi T. Kerenyi Z. Gyimesi A. Shoustov S. et al. (2003) Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J Clin Endocrinol Metab 88: 1637–1645.
23. Pendsey S. Dhanvijay V. Joshi P. (2002) Efficacy of pioglitazone as an add on drug with insulin, glibenclamide and metformin in patients with uncontrolled type 2 diabetes mellitus. Diabetologia Croatia 31: 51–57.
24. Pfützner A. Schöndorf T. Tschöpe D. Lobmann R. Merke J. Müller J. et al. (2011) PIOfix‑Study: Effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia. Diabetes Technol Ther 13: 637-643.
25. Razavizade M. Jamali R. Arj A. Matini S. Moraveji A. Taherkhani E. (2013) The effect of pioglitazone and metformin on liver function tests, insulin resistance, and liver fat content in nonalcoholic Fatty liver disease: a randomized double blinded clinical trial. Hepat Mon 13: e9270.
26. Sanyal A. Chalasani N. Kowdley K. McCullough A. Diehl A. Bass N. et al. (2010) Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 362: 1675–1685.
27. Spanakis E. Golden S. (2013) Race/ethnic difference in diabetes and diabetic complications. Curr Diab Rep 13: 814–823.
28. You S. Kim B. Hong S. Ahn C. Lim D. (2010) The effects of pioglitazone in reducing atherosclerosis progression and neointima volume in type 2 diabetic patients: prospective randomized study with volumetric intravascular ultrasonography analysis. Korean Circ J 40: 625–631.
29. Yki-Järvinen H. (2004) Thiazolidinediones. N Engl J Med 351: 1106–1118.
30. Waugh J. Keating G. Plosker G. Easthope S. Robinson D. (2003) Pioglitazone: A review of its use in Type 2 diabetes mellitus. Drugs 66: 340–341.
31. Zenari L. Marangoni A. (2013) What are the preferred strategies for control of glycaemic variability in patients with type 2 diabetes mellitus? Diabetes Obes Metab 15(Suppl. 2): 17–25.
32. Zou C. Hu H. (2013) Use of pioglitazone in the treatment of diabetes: effect on cardiovascular risk. Vasc Health Risk Manag 9: 429–433.